Avidity Biosciences, Inc.
DelistedCIK 1599901fmd_0KQN282G49VKPA61SR304F2E7KManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Dec 31, 2025, 29 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 2 | 7 | 9 | 9 | 10 | 11 | 19 |
| Research and development | 8 | 15 | 38 | 101 | 150 | 191 | 304 | 559 |
| Total operating expenses | 11 | 20 | 51 | 127 | 188 | 245 | 390 | 765 |
| Operating income | (10) | (17) | (44) | (118) | (179) | (236) | (379) | (746) |
| Interest expense | 1 | 7 | 0 | 0 | 0 | – | – | – |
| Other non-operating income (expense) | (1) | (7) | (0) | 0 | 5 | 23 | 57 | 61 |
| Income before taxes | – | – | – | – | – | (212) | (322) | (685) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | (212) | (322) | (685) |
| Net income | (11) | (25) | (44) | (118) | (174) | (212) | (322) | (685) |